The latest announcement is out from Control Bionics Ltd. ( (AU:CBL) ).
Control Bionics Limited announced an investor webinar to discuss its quarterly results and recent advancements. The company is enhancing its market position with innovative products like the NeuroNode and DROVE, and is expanding into new sectors with the NeuroStrip®, potentially impacting its operations and stakeholder interests.
More about Control Bionics Ltd.
Control Bionics is an Australian medical device company specializing in Electromyography technology, aimed at assisting patients with communication challenges due to conditions like Motor Neurone Disease and Amyotrophic Lateral Sclerosis. Their core product, the NeuroNode, is a wireless wearable device that enables communication through EMG signals. The company also offers the DROVE autonomous wheelchair module and is expanding into new markets with the NeuroStrip® device. Control Bionics operates in North America, Australia, Singapore, and Japan.
YTD Price Performance: -40.0%
Average Trading Volume: 231,042
Technical Sentiment Signal: Buy
Current Market Cap: A$10.61M
Learn more about CBL stock on TipRanks’ Stock Analysis page.